Abstract
The powerful methods for analyzing survival data (particularly censored survival data) that were introduced in the late 1960’s and early 1970’s represented major advances in the statistical assessment of such data. It is important to recognize, however, that these may not always be most appropriate to address the fundamental study question in any situation in which time-to-event techniques could be applied. In this paper, several such situations are considered, and the particular implications for regulatory decision-making are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abraham, E., Wunderink, R., Silverman, H., et al. (1995). Efficacy and safety of monoclonal antibody to human tumor necrosis factor and in patients with sepsis syndrome. Journal of the American Medical Association, 273, 934–941.
Anderson, P. K., Borgan, O., Gill, R. D., and Keiding, N. (1993). Statistical Models Based on Counting Processes. New York: Springer-Verlag.
Bone, R. C., Fisher, C. J. Jr., Clemmer, T. P., et al. (1989). Sepsis syndrome: a valid clinical entity. Critical Care Medicine, 17, 389–393.
Centers for Disease Control. (1992). 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 41, 1–35.
Cox, D. R. (1972). Regression models and life tables (with discussion). Journal of Royal Statistical Society, Series B, 34, 187–220.
Fisher, C. J. Jr., Dhainaut J. F. A., Opal, S. M., et al. (1994). Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Journal of the American Medical Association, 271, 1836–1843.
Fleiss, J. L. (1981). Statistical Methods for Rates and Proportions. New York: Wiley.
Fleming, T. R. and Harrington D. P. (1991). Counting Processes and Survival Analysis. New York: Wiley.
Greenman, R. L., Schein, R. M. H., Martin, M. A., et al. (1991). A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. Journal of the American Medical Association, 266, 1097–1102.
Hughes, M. D. (1997). Power considerations for clinical trials using multivariate time-to-event data. Statistics in Medicine, in press.
Knaus, W. A., Harrell, F. E., Fisher, C. J. Jr., et al. (1993). The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. Journal of the American Medical Association, 35, 861–867.
Legier, J. M., Lefkopoulou, M., Ryan, L. M. (1995). Efficiency and power of tests for multiple binary outcomes. Journal of the American Statistical Association, 90, 680–693.
Mantel, N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163–170.
Neaton, J. D., Wentworth, D. H., Rhame, F., et al. (1994). Methods for studying interventions: considerations in choice of a clinical endpoint for AIDS clinical trials. Statistics in Medicine, 13, 2107–2125.
O’Brien, P. C. (1984). Procedures for comparing samples with multiple endpoints. Biometrics, 40, 1079–1087.
Parrillo SE, Parker MM, Natanson C., et al. (1990). Septic shock in humans. Annals of Internal Medicine, 113, 227–242.
Prentice R.L., Williams B.J. and Peterson A.V. (1981). On the regression analysis of multivariate failure time data. Biometrika, 68, 373–379.
Rubenstein, L. V., Gail, M. H., and Santner, T. J. (1981). Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. Journal of Chronic Disease, 34, 469–479.
Siegel, J. P. (1997). Discussion of the paper by L. J. Wei and D. V. Glidden on “An overview of statistical methods for multiple failure time data in clinical trials”. Statistics in Medicine, in press.
Tang, D. L, Geller, N. L., and Pocock, S. J. (1993). On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics, 49, 23–30.
Therneau, T. M. (1997). Extending the Cox model. In Proceedings of the First Seattle Symposium in Bio statistics: Survival Analysis, Eds. D. Y. Lin and T. R. Fleming, pp. xxx–xxx. New York: Springer-Verlag.
Wei, L. J., Lin, D. Y., and Weissfeld, L. (1989). Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association, 84, 1065–1073.
Ziegler, E. J., Fisher, C. J. Jr., Sprung, C. L., et al. (1991). Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. New England Journal of Medicine, 324, 429–436.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag New York, Inc.
About this paper
Cite this paper
Ellenberg, S.S., Siegel, J.P. (1997). Survival Analysis in the Regulatory Setting. In: Lin, D.Y., Fleming, T.R. (eds) Proceedings of the First Seattle Symposium in Biostatistics. Lecture Notes in Statistics, vol 123. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-6316-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-4684-6316-3_12
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-94992-5
Online ISBN: 978-1-4684-6316-3
eBook Packages: Springer Book Archive